文章基本信息

标题：Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population
本地全文：下载
作者：Lena Tschiderer ; Lisa Seekircher ; Lukas Richter 等
期刊名称：iScience
印刷版ISSN：2589-0042
出版年度：2022
卷号：25
期号：11
页码：1-14
DOI：10.1016/j.isci.2022.105380
语种：English
出版社：Elsevier
摘要：SummaryThis study aimed to determine the impact of ultra-rapid rollout vaccination on incidence of SARS-CoV-2 infection. Vaccination with BNT162b2 was provided to 66.9% of eligible residents of the Schwaz district in Tyrol, Austria, within six days per dose (first dose: 11–16 March 2021, second dose: 8–13 April 2021). Of 11,955 individuals enrolled at nine vaccination centers (median age 44.6 years; 51.3% female), 71 had incident SARS-CoV-2 over a six-month follow-up. Incidence rates per 100,000 person-weeks were 92.3 (95% confidence interval [CI]: 70.8–120.2) at weeks 1–5 and 6.4 (3.9–10.4) at ≥6 weeks after dose 1. In these two periods, effectiveness of the vaccination campaign to reduce incident SARS-CoV-2 was 58.6% (50.8%–65.2%) and 91.1% (89.6%–92.3%) in study participants and 28.3% (23.1%–33.0%) and 64.0% (61.7%–66.1%) in the Schwaz district, compared with districts with slower vaccination rollout. Therefore, the vaccination campaign in the Schwaz district illustrates the impact of accelerated vaccination rollout in controlling the pandemic.Graphical abstractDisplay OmittedHighlights•This study accompanied an ultra-rapid rollout vaccination campaign in Austria•66.9% of eligible residents of the Schwaz district received BNT162b2 within 6 days•Over six months, SARS-CoV-2 incidence rate was 22.8 per 100.000 person-weeks•Effectiveness of the vaccination campaign was 91.1% at ≥6 weeks after the 1stdoseHealth sciences; Population; Immunology